| scholarly article | Q13442814 |
| P50 | author | Trish M Perl | Q90224123 |
| Scott K Fridkin | Q92321391 | ||
| Fred C Tenover | Q106114447 | ||
| Linda K. McDougal | Q115867930 | ||
| P2093 | author name string | William R Jarvis | |
| Jasmine Mohammed | |||
| Jeff Hageman | |||
| Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group | |||
| P2860 | cites work | Staphylococcus aureus infections | Q28131787 |
| Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know | Q31704853 | ||
| Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve | Q33181940 | ||
| Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group | Q33852247 | ||
| Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates | Q33978642 | ||
| Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review | Q34192576 | ||
| Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk | Q41714469 | ||
| Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin | Q45199316 | ||
| The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. | Q54105049 | ||
| Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. | Q55067143 | ||
| National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, issued August 2001 | Q56898125 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | United States of America | Q30 |
| vancomycin | Q424027 | ||
| Staphylococcus aureus | Q188121 | ||
| P304 | page(s) | 429-439 | |
| P577 | publication date | 2003-01-31 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. | |
| P478 | volume | 36 |
| Q29619731 | 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings |
| Q36083140 | A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA). |
| Q35549808 | A report on the first case of vancomycin-intermediate Staphylococcus aureus (VISA) in Hawai'i |
| Q33363226 | A review of linezolid: the first oxazolidinone antibiotic |
| Q92190635 | Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus in long-term care facilities in eastern Taiwan |
| Q37277083 | Acquired vancomycin resistance in clinically relevant pathogens |
| Q26829316 | Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines |
| Q28385050 | Additive effects of exogenous IL-12 supplementation and antibiotic treatment in infection prophylaxis |
| Q49340072 | Analysis of Morphologically Similar Staphylococcus aureus Colonies for Assessment of Phenotypic and Genotypic Correlation |
| Q35744321 | Antibacterial resistance |
| Q35588850 | Antibiotic Resistance in the Treatment of Staphylococcus aureus Keratitis: a 20-Year Review |
| Q36338182 | Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection |
| Q36283731 | Antibiotic resistance in Staphylococcus aureus and its relevance in therapy |
| Q36325685 | Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci |
| Q38023661 | Antimicrobial resistance among Gram-positive pathogens in Saudi Arabia |
| Q24676363 | Antimicrobial resistance: the example of Staphylococcus aureus |
| Q46127360 | Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance |
| Q36382134 | Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America |
| Q38010783 | Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection |
| Q64106833 | Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea |
| Q36094925 | Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. |
| Q37124131 | Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection |
| Q41812641 | Clinical evaluation of the DiversiLab microbial typing system using repetitive-sequence-based PCR for characterization of Staphylococcus aureus strains |
| Q40542104 | Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus |
| Q38425879 | Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus |
| Q38099554 | Clinical management of septic arthritis |
| Q34157657 | Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children |
| Q35745242 | Confronting bacterial resistance in healthcare settings: a crucial role for microbiologists |
| Q38123255 | Current and prospective treatments for multidrug-resistant gram-positive infections. |
| Q36520635 | Dalbavancin: a novel lipoglycopeptide antibacterial |
| Q37625160 | Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. |
| Q42278779 | Developing New Antimicrobial Therapies: Are Synergistic Combinations of Plant Extracts/Compounds with Conventional Antibiotics the Solution? |
| Q41915895 | Development and stability studies of novel liposomal vancomycin formulations. |
| Q40758601 | Emergence of a small colony variant of vancomycin-intermediate Staphylococcus aureus in a patient with septic arthritis during long-term treatment with daptomycin |
| Q36718474 | Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections |
| Q59269733 | Endocarditis caused by methicillin-susceptible Staphylococcus aureus with reduced susceptibility to vancomycin: a case report |
| Q30871144 | Epidemiologic data and pathogen genome sequences: a powerful synergy for public health |
| Q42752989 | Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. |
| Q40947815 | Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. |
| Q42948108 | Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus |
| Q34057324 | Exposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus |
| Q41016957 | First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia |
| Q36118613 | First report of vancomycin-intermediate resistance in sequence type 72 community genotype methicillin-resistant Staphylococcus aureus |
| Q80815497 | Foot Infections in Diabetic Patients |
| Q37546815 | Frequency of susceptibility testing for patients with persistent methicillin-resistant Staphylococcus aureus bacteremia |
| Q37850450 | From lead management to implanted patient management: indications to lead extraction in pacemaker and cardioverter-defibrillator systems |
| Q36876054 | Genetic Characterization of Methicillin Resistant and Sensitive, Vancomycin Intermediate Staphylococcus aureus Strains Isolated from Different Iranian Hospitals |
| Q98164449 | Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis |
| Q24241924 | Gloves, gowns and masks for reducing the transmission of meticillin-resistant Staphylococcus aureus (MRSA) in the hospital setting |
| Q38239460 | Glycopeptide antibiotics: back to the future. |
| Q38545589 | Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile. |
| Q22241905 | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia |
| Q36315377 | Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). |
| Q36409465 | Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. |
| Q45019889 | Has vancomycin-resistant Staphylococcus aureus started going it alone? |
| Q36452459 | Health care-associated endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin |
| Q35784289 | Hetero-vancomycin-intermediate methicillin-resistant Staphylococcus aureus isolate from a medical center in Las Cruces, New Mexico |
| Q36692468 | Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance |
| Q36233549 | Impact of community-associated, methicillin-resistant Staphylococcus aureus on management of the skin and soft tissue infections in children |
| Q35344720 | Impact of methicillin-resistant Staphylococcus aureus prevalence among S. aureus isolates on surgical site infection risk after coronary artery bypass surgery |
| Q39955054 | In vitro activity of the new quinolone WCK 771 against staphylococci |
| Q33559139 | In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa |
| Q41066970 | Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period |
| Q42042890 | Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin |
| Q46826194 | Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia |
| Q37302793 | Intermediate vancomycin susceptibility in a community-associated MRSA clone |
| Q42424814 | Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus? |
| Q35023343 | Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia |
| Q44603331 | Linezolid for the treatment of complicated skin and skin structure infections in children |
| Q35871928 | Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections |
| Q40327481 | Low prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates among Connecticut veterans |
| Q36025384 | Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective. |
| Q58835164 | Management of MRSA-positive eye swabs and the potential advantages of chloramphenicol availability in the United Kingdom |
| Q26829312 | Mechanisms of vancomycin resistance in Staphylococcus aureus |
| Q35801736 | Methicillin-resistant Staphylococcus aureus and beyond: what's new in the world of the golden staph? |
| Q35662677 | Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis). |
| Q33290348 | Methicillin-resistant Staphylococcus aureus: a 5-year review of surveillance data in a tertiary care hospital in Saudi Arabia |
| Q38171759 | Methicillin-resistant Staphylococcus aureus: an evolving pathogen |
| Q34453707 | Meticillin-resistant Staphylococcus aureus |
| Q36328966 | Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains |
| Q28475777 | Modeling of the bacterial mechanism of methicillin-resistance by a systems biology approach |
| Q90583410 | Molecular Detection of Methicillin-Heat-Resistant Staphylococcus aureus (MHRSA) Strains in Pasteurized Camel Milk in Saudi Arabia |
| Q80484614 | Nosocomial bacteraemia caused by Staphylococcus aureus |
| Q36237707 | Nosocomial bacterial infections in Intensive Care Units. I: Organisms and mechanisms of antibiotic resistance |
| Q39743944 | Novel Observations in 11 Heteroresistant Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Strains from South India. |
| Q36086423 | Oritavancin for acute bacterial skin and skin structure infections |
| Q28382940 | PRP as a new approach to prevent infection: preparation and in vitro antimicrobial properties of PRP |
| Q47236135 | Penetration of linezolid into synovial fluid and muscle tissue after elective arthroscopy |
| Q45127594 | Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections |
| Q89926973 | Plantaricin NC8 αβ exerts potent antimicrobial activity against Staphylococcus spp. and enhances the effects of antibiotics |
| Q64231611 | Plantaricins markedly enhance the effects of traditional antibiotics against Staphylococcus epidermidis |
| Q36644689 | Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter? |
| Q36037687 | Predicting risk for death from MRSA bacteremia |
| Q35940556 | Predictors of mortality in Staphylococcus aureus Bacteremia |
| Q43162354 | Prevalence and accessory gene regulator (agr) analysis of vancomycin-intermediate Staphylococcus aureus among methicillin-resistant isolates in Taiwan--SMART program, 2003. |
| Q44890185 | Prevalence of isolates with reduced glycopeptide susceptibility in orthopedic device-related infections due to methicillin-resistant Staphylococcus aureus. |
| Q37274726 | Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. |
| Q37059039 | Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database |
| Q35759049 | Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria |
| Q33883752 | Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function |
| Q24646677 | Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications |
| Q34783668 | Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia |
| Q35619094 | Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era |
| Q80215627 | Reversion of resistance in relapsing infection caused by a glycopeptide-intermediate methicillin-resistant Staphylococcus aureus isolate |
| Q36153912 | Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus |
| Q33883648 | Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations |
| Q34374880 | Staphylococcus aureus ocular infection: methicillin-resistance, clinical features, and antibiotic susceptibilities |
| Q35541702 | Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods |
| Q35882353 | Staphylococcus aureus with reduced susceptibility to vancomycin |
| Q26796560 | Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates |
| Q37256413 | The first vancomycin-intermediate Staphylococcus aureus strains isolated from patients in Thailand |
| Q64934784 | The impact of vancomycin trough concentrations on outcomes in non-deep seated infections: a retrospective cohort study. |
| Q36086420 | The posttranslocational chaperone lipoprotein PrsA is involved in both glycopeptide and oxacillin resistance in Staphylococcus aureus |
| Q36779557 | The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus |
| Q30433201 | The state of the science |
| Q39513906 | Toward Overcoming Staphylococcus aureus Aminoglycoside Resistance Mechanisms with a Functionally Designed Neomycin Analogue |
| Q27015976 | Treatment of Gram-positive infections in critically ill patients |
| Q42914487 | Treatment of Infections Caused By Antimicrobial-Resistant Gram-Positive Bacteria |
| Q36607415 | Treatment of Pseudomonas aeruginosa infection in critically ill patients |
| Q43433837 | Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility |
| Q37322249 | Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics |
| Q42369114 | Trend of vancomycin susceptibility of staphylococci at a level 1 trauma centre of India |
| Q36528714 | Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible? |
| Q42871030 | Vancomycin MIC Susceptibility Testing of Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Isolates: A Comparison Between Etest® and an Automated Testing Method |
| Q43117809 | Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years |
| Q95355781 | Vancomycin Resistance in Staphylococcus aureus |
| Q35768102 | Vancomycin Use in Patients Discharged From the Emergency Department: A Retrospective Observational Cohort Study |
| Q36847287 | Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections |
| Q34433066 | Vancomycin revisited - 60 years later |
| Q42153532 | Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates |
| Q81103956 | [Clinical guidelines for the treatment of nosocomial pneumonia in Latin America: an interdisciplinary consensus document. Recommendations of the Latin American Thoracic Society] |
| Q53875857 | [Epidemiology and risk factors for acquiring multidrug resistant Staphylococcus] |
Search more.